Rhythm Pharmaceuticals (NASDAQ:RYTM) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here’s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Rhythm Pharmaceuticals to report an earnings per share (EPS) of $-0.78.
Anticipation surrounds Rhythm Pharmaceuticals’s announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
The company’s EPS missed by $0.10 in the last quarter, leading to a 5.26% drop in the share price on the following day.
Here’s a look at Rhythm Pharmaceuticals’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.72 | -0.67 | -0.68 | -0.73 |
| EPS Actual | -0.82 | -0.75 | -0.81 | -0.72 |
| Price Change % | -5.26 | 1.63 | -6.05 | -0.60 |
Tracking Rhythm Pharmaceuticals’s Stock Performance
Shares of Rhythm Pharmaceuticals were trading at $98.65 as of February 24. Over the last 52-week period, shares are up 85.83%. Given that these returns are generally positive, long-term shareholders are likely bullish going into …